Search results
Results from the WOW.Com Content Network
Statins appear to be effective at preventing cardiovascular disease and death in older adults, according to new research. Most clinical trials evaluating statins have not included people 75 and ...
When examining the cost-effectiveness of statin use in older adults, the researchers report that statins were cost-effective, with the cost per quality-adjusted life years gained below £3,502 ...
The findings show a decrease in mortality among people 60 years of age and older — including people over the age of 85 — who took statins. The study is published in Annals of Internal Medicine .
[5] [65] Over 5 years of treatment statins result in 75 cases of diabetes, 7.5 cases of bleeding stroke, and 5 cases of muscle damage per 10,000 people treated. [34] This could be due to the statins inhibiting the enzyme (HMG-CoA reductase), which is necessary to make cholesterol, but also for other processes, such as CoQ 10 production, which ...
Because low- to moderate dose statins are strongly recommended by the United States Preventive Services Task Force (USPSTF) for primary prevention of cardiovascular disease in adults aged 40–75 years who are at risk, [32] the Patient Protection and Affordable Care Act (PPACA) in the United States requires most health insurance plans to cover ...
A 2010 published meta-analysis found for every 255 patients taking a statin for 4 years, one additional case of diabetes would occur whilst preventing 5.4 major coronary events. [27] Some drugs interact with statins in a way that increases the risk of muscle injury called myopathy, characterized by unexplained muscle weakness or pain.
Over 17 million people may be taking statins they do not need. ... PCE estimated an 8% risk of developing atherosclerotic cardiovascular disease over 10 years. Using PREVENT, this figure dropped ...
Type 2 statins Statins that are fully synthetic and have larger groups linked to the HMG-like moiety are often referred to as type 2 statins. One of the main differences between the type 1 and type 2 statins is the replacement of the butyryl group of type 1 statins by the fluorophenyl group of type 2 statins.